الصفحة الرئيسية

كلية الصيدلة \ الكيمياء الصيدلة

كامل عبدالرحيم متولي بيومي

السيرة الذاتية
نسبة اكتمال الملف الشخصي
الجنسية المصرية
التخصص العام الكيمياء الصيدلية
التخصص الدقيق الكيمياء الدوائية
المسمى الوظيفي استاذ
الدرجة العلمية (المرتبة) دكتوراه

نبذه مختصرة

Dr Kamel A Metwally, Professor of Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Tabuk I had PhD in Medicinal Chemistry from Zagazig University (Egypt), according to a channel program with Virginia Commonwealth University (Virginia, USA), under the title "design and synthesis of novel 5-HT2 ligands" Master degree in Medicinal Chemistry, was awarded from Zagazig University under the title "synthesis and pharmacological study of some new arylpropionic acid derivatives My research interests include the design and synthesis of novel tyrosine kinase inhibitors as anticancer agents design and synthesis of aldose reductase inhibitors as potential therapeutic agents for the prevention of diabetic complications and design and synthesis of novel anticancer agents targeting tubulin

المؤهلات العلمية

PhD 1998: Medicinal Chemistry, Virginia Commonwealth University (USA) according to a channel program with Zagazig University (Egypt) Title of dissertation: “Design and synthesis of novel 5-HT2 ligands MSc 1995: Medicinal Chemistry, Faculty of Pharmacy, Zagazig University Title of thesis: “Synthesis and pharmacological study of some new arylpropionic acid derivatives BSc 1990:Phar maceutical Sciences, Faculty of Pharmacy, Zagazig University “Excellent with honor degree the first out of ~ 150 students

الاهتمامات البحثية

Design and synthesis of novel tyrosine kinase inhibitors as anticancer agents Design and synthesis of aldose reductase inhibitors as potential therapeutic agents for the prevention of diabetic complications Design and synthesis of novel anticancer agents targeting tubulin

الخبرات والمناصب الإدارية

• Supervisor of measurement, assessment, and evaluation unit, Faculty of Pharmacy, University of Tabuk, Tabuk, Kingdom of Saudi Arabia (May 2021 to date) • Supervisor of FPUT strategic plan implementation, Faculty of Pharmacy, University of Tabuk, Tabuk, Kingdom of Saudi Arabia (May 2021 to date) • Professor of Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Tabuk, Tabuk, Kingdom of Saudi Arabia (March 2021 to date) • Head of Medicinal Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt (August 2018 – March 2021) • Professor, Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt (March 2018 - to date) • Assistant Professor, Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt (July 2012- March 2018) • Member, “Scientific Council of King Faisal University, (Two terms, starting April 2010) Selected unanimously by King Faisal University Council and approved by Saudi Minister of Higher Education in both terms • Member, “Translation, Authorship and Publication Center of King Faisal University (Two terms, starting January 2010) Selected unanimously by King Faisal University Council • Associate Professor, Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, KSA (September 2006- July 2012) • Lecturer, Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University (October 2001- September 2006) • Part-time Lecturer, Department of Pharmaceutical Chemistry, School of Pharmacy, Misr International University (MIU), Obour City, Egypt (September 2003 to September 2005) • Postdoctoral Fellow, Department of Medicinal Chemistry, School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Virginia, USA funded by the American university (October 2000- October 2001) • Lecturer, Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University (October 1998- October 2000) • Teaching Assistant Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University (April 1998 - October 1998) • PhD research scholar, School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Virginia, USA (April 1996 to April 1998) • Teaching Assistant Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University (March 1995- April 1996) • Demonstrator Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University (September 1990- March 1995)

الجدول الدراسي
اليوم المادة الوقت
من إلى
الأحد Introductory Medicinal Chemistry 09:00 12:00
الأحد Office hours (3rd year - Male - 148) 12:00 14:00
الإثنين Academic advising 09:00 11:00
الإثنين Clinical Biochemistry (Field training) 13:00 15:00
الثلاثاء Office hours (4th year - Male - 1536) 12:00 14:00
الأربعاء Medicinal Chemistry-2 (Female section) 08:00 11:00
الأربعاء Office hours (4th year - Female - 104) 11:00 13:00
الخميس Medicinal Chemistry-2 (Male section) 10:00 13:00
الخميس Field Pharmaceutical training-3 13:00 17:00
الأبحاث والمؤلفات
  • https://scholargooglecom/citations?user=3C-ZrXMAAAAJ
جوائز التميز
  • 1- The First of Class Honor (1990): Faculty of Pharmacy, Zagazig University 2- Egyptian Syndicate of Pharmacists Award for distinguished academic pharmacists (1995) 3- Egyptian Syndicate of Pharmacists Award for distinguished academic pharmacists (1999) 4- Zagazig University Research Award for distinguished researchers (2007) 5- Outstanding reviewer 2015, European Journal of Medicinal Chemistry (2015) 6- Zagazig University Research Award for distinguished researchers (2016)
المشاريع البحثية
اسم المشروع وصف المشروع
Investigation of the potential physical and mental enhancement effects of Sesamol, Melatonin, and CoQ10 in Alzheimer’s Disease in rats Background: Alzheimer’s disease (AD) is a neurodegenerative disorder that characterized by a progressive decline of cognitive abilities Physical and mental activities (PH&M) have been related to better cognitive function in older adults Cognitive engagement and physical activities have been associated with decreased risk of AD Sesamol, Melatonin, CoQ10 are neuroprotective drugs that possess anti-inflammatory and antioxidant properties Aim: To evaluate the potential enhancement of Sesamol, Melatonin, CoQ10 and their selected combinations on the mental and physical activities on AD affected rats Methods: AD will be induced by ALCl3 (70mg/kg IP) every day for five weeks Physical and Mental activities PH&M exposed (swimming and Open field maze test) Sesamol, Melatonin, CoQ10 and their selected combinations will be administrated in parallel with ALCl3 (protective model) The effect of treatments will be assessed on animal behavior, brain neurotransmitters, biochemical changes in the brain monoamines, oxidative stress, pro-inflammatory cytokines, apoptosis Moreover, Histopathological changes in different brain regions, liver, kidney and heart and ultrastructural examinations will be performed
Design and synthesis of novel tubulin polymerization inhibitors as anticancer agents - Principal Investigator, KFU Deanship of Scientific Research grants 2009-2010: Grant number (10032/2009) Cancer is a major health care problem as one of the leading causes of death worldwide Recent revolutionary advances in the field of molecular biology and cancer cell biology have created new targets for antitumor compounds Amongst, tubulin retrieved a unique place as the most attractive target for anticancer drug research in the past decade In the present investigation, a systematic structure-activity relationship study will be formulated for pyrimido[4,5-c]quinolin-1(2H)-ones recently reported by us in order to “fine-tune their cytotoxicity and optimize binding to tubulin
Computer-assisted design and synthesis of novel aldose reductase inhibitors for prevention of diabetic complications - Principal Investigator, KACST (King Abdul-Aziz City for Science and Technology) grants 2010-2011: Grant number (APR-30-233) Diabetes mellitus is emerging as a major public health problem in Saudi Arabia The prevalence of diabetes in Saudi Arabia is about 24%, one of the highest in the world This pandemic will have a significant impact on the meager health resources of the kingdom, as diabetes is a chronic disease with devastating complications, including premature atherosclerotic cardiovascular diseases, sight-threatening retinopathy, renal failure and neuropathic diseases In addition, these complications lead to the exclusion of a significant proportion of the effective productive power of the society Compelling evidences accumulated over the past three decades clearly link aldose reductase enzyme, the key enzyme of the polyol pathway, with the initiation and progression of diabetic complications Consequently, inhibition of aldose reductase provides an attractive strategy to prevent or delay the onset of the complications of chronic diabetes Two major classes of aldose reductase inhibitors are currently available, acetic acid derivatives and the hydantoins and their bioisosteres Unfortunately, the majority of these drugs were withdrawn in different phases of clinical trials due to lack of efficacy, oral activity or due to adverse reactions The hydantoins and related bioisosteres are known to have better pharmacokinetics compared to acetic acid derivatives Among the compounds reported to have potent in vitro aldose reductase inhibitory activity are the indole-based acetic acid derivatives Yet as might be expected, these compounds may have low in vivo activity due to poor pharmacokinetics In this research project, we propose that replacement of the acetic acid moiety in this particular class of compounds by a hydantoin nucleus will significantly improve pharmacokinetics Meanwhile, high potency will be retained because the hydantoin ring is pharmacophoric to aldose reductase inhibition Selection of the target compounds was based on molecular modeling studies conducted on a number of spirohydantoins of certain fused indoles such as the carbazoles
In silico screening of coumarin-based phytoproducts of Ferula asafoetida as potential therapeutic candidates Assafoetida is the oleogum resin obtained from the rhizomes and roots of the herbaceous perennial plant Ferula assafoetida from the Umbelliferae (Apiaceae) family The oleogum resin assafoetida is sold in Saudi Arabia under the name “Haltit or “Tyib It is traditionally used for the treatment of different diseases, such as asthma, flatulence, stomachache, epilepsy, intestinal parasites, weak digestion, and influenza It has also been reported recently to have anti-diabetic, antihypertensive, antioxidant, antiviral, antifungal, cancer chemopreventive, and antispasmodic activities In terms of chemical constituents, the resin fraction contains ferulic acid, sesquiterpene coumarins and other terpenoids Recent studies have revealed that assafoetida sesquiterpene coumarins display antiviral, antiangiogenic, and antitumor activities These findings motivated us to perform a molecular modelling study to screen the potential therapeutic utilities of the coumarin constituents of assafoetida Literature survey through known medical research engines and SciFinder search revealed that coumarin-based compounds bind to four main target proteins namely, vitamin K peroxide reductase (VKOR), monoamine oxidase B (MAO-B), acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) Compounds targeting VKOR have potential therapeutic utility as anticoagulants, while those targeting MAO-B have potential therapeutic utility in Parkinson’s disease On the other hand, AChE and BChE are implicated in the pathophysiology of Alzheimer’s disease This research proposal aims at virtually screening the potential target proteins for the coumarin-based active constituents of Ferula assafoetida through molecular docking followed by a molecular dynamic simulation study, using the well-known MOE molecular modeling software The research proposal belongs to a capstone graduation research project at the Faculty of Pharmacy, University of Tabuk, conducted by two Pharm D students: Osama Alsharif and Abdulaziz Alghuzawi The project is under the supervision of Dr Kamel Metwally, Professor of Medicinal Chemistry at the college who has many publications in the field of molecular modeling
معلومات التواصل
البريد الإلكتروني : kametwally@UT.EDU.SA
3912

الخصوصية وملفات تعريف الارتباط
هذا الموقع يستخدم ملفات تعريف الارتباط الخاصة للتأكد من سهولة الاستخدام وضمان تحسين تجربتك أثناء التصفح. من خلال الاستمرار في تصفح هذا الموقع، فإنك تقر بقبول استخدامنا لملفات تعريف الارتباط. الشروط والأحكام.